2015-06-05 18:31:18 UTC

IBD Treatment

Clinical Snapshots

About

This AGA Clinical Snapshot is an executive summary of Dr. Sandborn's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.

Takeaways

1. Understand near-term and intermediate-term potential treatment options for patients who are failing currently available immunosuppressive and biologic therapy.

2. Many patients fail biologic therapy with anti-TNF agents and anti-integrin therapy with vedolizumab (anti-α4β7 antibody), through a variety of mechanisms including primary non-response, secondary lost response, and intolerance.

3. Treatment options switching within and out of class with alternative selective anti-integrin agents, sphingosine 1 phosphate (S1P) receptor modulators, Janus kinase (JAK) inhibitors, anti-interleukin 12/23 and anti- IL 23, and Smad7 antisense.

About the Instructors

William J. Sandborn, MD, AGAF, University of California, San Diego

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

What are the Future Selective Anti-integrin Therapies in Addition to the Currently Available Agent Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease?

In addition to the approved agent vedolizumab, there are three selective anti-integrin agents in development, anti-MAdCAM1 (PF-00547, 659, Pfizer), etrolizumab (anti-β7, rhumab beta 7, Genentech), anti-α4β7 (AMG181, Amgen) …

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.

Insurance Barriers Should Not Hinder Step Therapy Treatment for IBD

Dec. 13, 2017

AGA participated in a congressional briefing to highlight the need for physician use of step therapy treatment without barriers.